The Delhi High Court reinstated an injunction halting Zydus Lifesciences from selling ‘Sigrima,’ a cancer medication, due to patent infringement claims by F. Hoffmann-La Roche AG. Zydus has appealed this ruling to the Supreme Court. The case’s outcome may significantly impact patent rights and pharmaceutical sales in India.
